Zydus Cadila announces research Program to develop Coronavirus Vaccine

Ahmedabad: Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has initiated an accelerated research programme with multiple teams in India and Europe developing a vaccine for the novel coronavirus, 2019-nCoV (COVID-19) based on two approaches.

The first approach deals with development of a DNA vaccine against the major viral membrane protein responsible for the cell entry of the novel coronavirus, now called COVID19. The plasmid DNA would be introduced into the host cells, where it would be translated into the viral protein and elicit a strong immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

The second approach deals with development of a live attenuated recombinant measles virus vectored vaccine against COVID-19. The recombinant measles virus (rMV) produced by reverse genetics would express codon-optimised proteins of the novel coronavirus and will induce long-term specific neutralizing antibodies, which will provide protection from the infection.

Speaking on the development, Chairman of the Zydus Group, Mr. Pankaj R. Patel said, "There is an urgent and pressing need to develop a safe and efficacious vaccine that can prevent the spread of this deadly virus. Our researchers are working to bring a speedy solution to this most devastating outbreak in recent times."

The group's Vaccine Technology Centre in India which is working on the plasmid DNA vaccine also has wide ranging capabilities in developing and manufacturing different vaccines for unmet needs. The group was the first to develop and indigenously manufacture the vaccine to combat Swine Flu during outbreak in 2010.

The group's research arm in Europe, Etna Biotech is working on measles reverse genetics technology which has been used earlier to successfully develop the SARS-vaccine. The vaccines developed through this platform are safe, efficacious and large doses can be manufactured for which Zydus already has production facilities in place.

The company's robust manufacturing facilities for producing recombinant antigens and measles containing vaccines would enable rapid ramping up of the production for both vaccine candidates, once the proof-of-concept is established.

The Novel Coronavirus outbreak which started in December 2019 has so far infected over 67000 people and has claimed over 1500 lives

Read also: Zydus Cadila gets USFDA nod for Fluocinonide cream to treat skin conditions

Read also: Zydus Cadila gets USFDA nod for bowel disease drug Mesalamine suppositories